News | August 10, 2025
Wockhardt reports Q1 FY26 loss at Rs. 108 Cr
Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a
Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Cenexi reports an EBITDA breakeven for the quarter
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Subscribe To Our Newsletter & Stay Updated
